Implantable contact lens and preloaded IOL manufacturing will move to California in a consolidation
project now under way at STAAR Surgical.
Author: ModernMedecine
Welch Allyn facility earns LEED environmental certification
The Welch Allyn facility in Beaverton, OR, earned Leadership in Energy and Environmental Design (LEED)
certification from the U.S. Green Building Council.
FDA clears laser for cataract surgery incisions
The FDA approved OptiMedica’s Catalys Precision for creating single-plane and multi-plane arc
incisions in the cornea during cataract surgery.
Lucentis improves myopic choroidal neovascularization
ZURICH (Reuters) – Switzerland’s Novartis said on Wednesday new data for Lucentis demonstrated its
benefits in treating myopic choroidal neovascularization secondary to pathological myopia, which Novartis will seek
approval for.
Optomap system eases diabetic retinopathy assessment
NEW YORK (Reuters Health) – For grading diabetic retinopathy (DR) and clinically significant macular
edema (CSME), the Optomap Panoramic 200 (Optos) imaging device offers advantages over standard methods, German
researchers say.
Vision loss predicts less physical activity
NEW YORK (Reuters Health) – People whose vision has deteriorated in both eyes are less physically
active than people without vision loss, according to a new study.
Prompt bevacizumab helps curb macular edema
NEW YORK (Reuters Health) – Intraocular injections of bevacizumab (Avastin) are helpful in macular
edema (ME) due to central retinal vein occlusion (CRVO), Swedish researchers say – as long as they’re given
promptly.
Dry eye risk similar after laser vision surgeries
NEW YORK (Reuters Health) – Two laser surgeries used to correct blurry vision have a similar chance of
causing dry eyes, at least temporarily, a new study finds.
Gevokizumab receives orphan drug designation
Gevokizumab, a beta modulating antibody from XOMA Corp., has received FDA orphan drug designation for
the treatment of several types of non-infectious uveitis.
Retinal disease research gets $2.4 million boost
The Foundation Fighting Blindness is funding projects related to age-related macular degeneration,
retinitis pigmentosa, Leber’s congenital amaurosis, and Usher syndrome.
Allergan, Molecular Partners enter DARPin agreements
Allergan Inc. and Molecular Partners AG have entered into agreements to discover, develop, and
commercialize designed ankyrin repeat protein (DARPin) products.
Fibrin glue may cause TASS
Fibrin glue might be a potential cause of toxic anterior segment syndrome (TASS).
Laser surgery education gets $1 million boost
Ophthalmologists will have a new way to learn about advances in laser surgery next year, thanks to a
$1 million donation made to the American Academy of Ophthalmology.
Share tips with patients during Cataract Awareness Month
Share these tips with patients during Cataract Awareness Month, courtesy of the American Academy of
Ophthalmology and its EyeSmart program.
Phase II study for travoprost punctum plugs
Ocular Therapeutix Inc. is initiating a phase II clinical trial of OTX-TP2, a 2-month travoprost
punctum plug for treating ocular hypertension and glaucoma.
Accomodative changes in the ACD less pronounced in high myopia
A study found that accommodative changes in the central anterior chamber depth (ACD) of patients with
high myopia were less pronounced than emmetropic eyes.
VICTUS femtosecond laser in action (VIDEO), capsulotomy creation
A short video of capsulotomy creation with the VICTUS femtosecond laser.
Insight Software ranked on Inc. 500|5000 list
Insight Software, creators of My Vision Express, has been ranked number 2,067 on Inc.
magazine’s 31st annual Inc. 500|5000, a ranking of the nation’s fastest-growing private
companies.
JCAHPO taps Pearson VUE to offer simulated exams
The Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) and Pearson VUE have entered
into an agreement to provide ophthalmic medical technicians access to computer-based multiple-choice and simulated
exams.
Enrollment begins for cataract surgery pain trial
Patient enrollment has begun in a phase III clinical trial of a low dose of bromfenac delivered via a
synthetic polymer-based formulation designed to extend the residence time of a drug (BromSite, InSite Vision) for
the reduction of pain and in…